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Abstract 
Background: Plasmodium vivax infections in humans or in new world monkeys pose research challenges that neces‑
sitate the use of alternative model systems. Plasmodium cynomolgi is a closely related species that shares genetic and 
biological characteristics with P. vivax, including relapses. Here, the haematological dynamics and clinical presentation 
of sporozoite‑initiated P. cynomolgi infections in Macaca mulatta (rhesus macaques) are evaluated over a 100‑day 
period.
Methods: Five M. mulatta were inoculated with 2000 P. cynomolgi B strain sporozoites. Parasitological and haema‑
tological data were collected daily to study the clinical presentations of primary infections and relapses. Peripheral 
blood and bone marrow aspirates were collected at specific time points during infection for future and retrospective 
systems biology analyses.
Results: Patent infections were observed between days 10 and 12, and the acute, primary infection consisted of 
parasitaemias ranging from 269,962 to 1,214,842 parasites/µl (4.42–19.5 % parasitaemia). All animals presented with 
anaemia, ranging from moderate (7–10 g/dl) to severe (<7 g/dl), based on peripheral haemoglobin concentrations. 
Minimum haemoglobin levels coincided with the clearance of parasites and peripheral reticulocytosis was evident 
at this time. Mild thrombocytopaenia (<150,000 platelets/µl) was observed in all animals, but unlike haemoglobin, 
platelets were lowest whenever peripheral parasitaemia peaked. The animals’ conditions were classified as non‑severe, 
severe or lethal (in one case) based upon their clinical presentation. The lethal phenotype presented uniquely with an 
exceptionally high parasitaemia (19.5 %) and lack of a modest reticulocyte release, which was observed in the other 
animals prior to acute manifestations. One or two relapses were observed in the four surviving animals, and these 
were characterized by significantly lower parasitaemias and minimal changes in clinical parameters compared to pre‑
infection values.
Conclusions: Rhesus macaque infections initiated by P. cynomolgi B strain sporozoites recapitulated pathology of 
human malaria, including anaemia and thrombocytopaenia, with inter‑individual differences in disease severity. 
Importantly, this study provides an in‑depth assessment of clinical and parasitological data, and shows that unlike the 
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Background
Malaria represents a constant burden and public health 
challenge in approximately 100 countries worldwide 
[1]. Plasmodium falciparum is responsible for the larg-
est number of cases and malaria-associated deaths, with 
extensive research efforts focused on understanding the 
basic biology and associated pathogenesis of this parasite 
species. Plasmodium vivax has also been recognized as 
a major contributor to the global burden of malaria, and 
numerous recent reports indicate infections can result in 
complications with lethal outcomes [2–5]. However by 
comparison, neglect of P. vivax is apparent, greatly due 
to the challenges associated with studying this species, 
which include the lack of a long-term in vitro culture sys-
tem or a rodent model that can support the entire life-
cycle and re-create critical aspects of P. vivax infections 
and disease as observed in humans [6–9].
Plasmodium vivax, as well as Plasmodium ovale, dif-
fer from the three other human malaria-causing spe-
cies (P. falciparum, Plasmodium malariae, Plasmodium 
knowlesi) because they can develop dormant liver-stage 
forms, known as hypnozoites [10]. Hypnozoites can 
activate and multiply, causing relapsing blood-stage 
infections days, months or years after the primary infec-
tion. Relapses may result in clinical disease and, impor-
tantly, provide the chance for gametocytes to encounter 
anopheline mosquito vectors and ensure transmission. 
New insights are needed to treat this liver-stage reser-
voir to ensure the elimination of relapses and blood-stage 
infections containing infectious gametocytes. Virtually 
nothing is known about the biology of relapse infections 
despite the fact that relapses are thought to be respon-
sible for as high as 96  % of vivax infections in differ-
ent parts of the world [11]. It is currently unclear how 
relapses are similar or different from primary infections, 
from a parasitological and clinical perspective, and the 
relative contribution of relapses to clinical malaria has 
been uncertain.
Understanding the course of primary and relapse 
infections, and specific mechanisms that result in vivax 
malaria pathogenesis, disease severity and recovery, are 
important goals. In particular, the identification of mech-
anisms that function in the peripheral blood and bone 
marrow resulting in the onset and recovery of malarial 
anaemia [12, 13] and thrombocytopaenia [14] may aid the 
search for novel interventions and therapeutic strategies 
to manage and/or alleviate these common complications. 
Headway has been made with the study of specimens iso-
lated from human patients living in endemic areas [15, 
16]; however, these studies are mostly restricted to one or 
a few small blood samples at the time of illness and treat-
ment. Furthermore, the analysis and interpretation of 
these studies can be affected by uncontrollable variables 
such as diet, medications, transmission characteristics, 
co-infections, and other maladies. These factors can con-
found associations of clinical signs and symptoms. Non-
human primate animal models can eliminate a number of 
these concerns, with experimental plans allowing for the 
study of specific biological, immunological or pathologi-
cal processes in a controlled, prospective and manipula-
ble environment.
Non-human primate models have contributed to the 
broad understanding of malaria biology, pathogenesis 
and immunity with regards to liver-stage and blood-
stage infections, and they have also been instrumental 
for screening vaccine and drug candidates or specific 
formulations [17–21]. Plasmodium vivax can be studied 
directly in New World monkey species, such as squir-
rel (Saimiri boliviensis) and owl (Aotus sp.) monkeys, 
and these models have been important, for example, in 
testing vaccine and drug candidates with parasite chal-
lenge infections [22, 23] and, recently, to identify and 
characterize blood-stage proteomes of P. vivax infected 
erythrocytes [24, 25]. However, due to the small size of 
these animals (~1 kg), which limits the amount of blood 
(or bone marrow) available for sampling, and the lack of 
validated reagents available to evaluate host physiologi-
cal and immunological responses, they are not ideal for 
extensive hypothesis testing in relation to malaria patho-
genesis, immune responses and recovery processes.
Plasmodium cynomolgi is a simian malaria parasite of 
Old World macaques that is genetically closely related to 
P. vivax [26, 27] and shares many biological similarities 
to the human parasite including the preferential invasion 
of reticulocytes [28, 29], development of unique infected 
red blood cell (RBC) structures called caveola-vesicle 
complexes [30, 31], and critically, the ability to form hyp-
nozoites that can reactivate and cause relapse infections 
[10, 18, 32, 33]. Macaques are closely related to humans, 
and a large variety of cross-reactive reagents for assessing 
primary infections, the relapses did not cause clinical malaria. Notably, this body of research has provided experimen‑
tal plans, large accessible datasets, and blood and bone marrow samples pertinent for ongoing and iterative systems 
biology investigations.
Keywords: Plasmodium vivax, Host‑pathogen interactions, Malaria, Non‑human primates, Rhesus, Anaemia, 
Thrombocytopaenia, Systems biology, Animal models
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host responses have been developed since these monkeys 
are model organisms for infectious diseases [34]. Young 
adult macaques (~5  kg or greater) can support longitu-
dinal Plasmodium infection studies that require repeated 
sampling within a short time frame. Macaca mulatta 
(rhesus monkey) and M. fascicularis genome sequences 
[35, 36] and the genome sequence of several strains of P. 
cynomolgi [26], have been characterized in recent years, 
enabling basic as well as systems biology studies of host-
parasite interactions.
Here, comprehensive analyses of sporozoite-initi-
ated, longitudinal infections of P. cynomolgi in rhesus 
macaques are presented with the long-term goal of using 
this model for systems biology investigations to better 
understand human malaria pathogenesis, particularly as 
it pertains to pathophysiological complications observed 
in sick patients and with regard to the impact of relapses 
on both the health of individuals and transmission [37]. 
Previous studies have utilized the P. cynomolgi-macaque 
model to understand the parasite’s basic biology and 
parasite kinetics, including the study of hypnozoites and 
relapses [20, 33, 38]. However, an extensive characteriza-
tion of the clinical and haematological perturbations that 
occur during the infections has not been reported, par-
ticularly on a daily basis.
Methods
Experimental design
The basic experimental design of this study is shown in 
Fig. 1a. The sampling strategy included a single pre-infec-
tion and six subsequent blood and bone marrow aspirate 
specimen collections during the infection at major infec-
tion or pathology presentation time points. The criteria 
for the collection of samples are described in Table 1 and 
adhered strictly to Institutional Animal Care and Use 
Committee (IACUC)-approved volume limits of 10 ml/
kg/month or 6.6  ml/kg/month if an animal was anae-
mic. Adjustments were made as to when samples were 
acquired based on each animal’s parasitological and 
haematological kinetics. Clinical signs and symptoms 
observed by trained veterinary staff were also taken into 
consideration daily. All samples collected for an experi-
mental period satisfied at least one or more of the pre-
defined clinical criteria (Table  1). As expected, some 
individuals required pharmacological and/or clinical sup-
port during the acute, primary infection. Blood and bone 
marrow aspirate specimens were acquired prior to such 
clinical interventions.
In addition to collecting samples for analysis at major 
points during the infections, this study was also designed 
to collect clinical data on a daily basis. The aim of these 
collections was to develop highly resolved clinical kinet-
ics. To achieve this goal, the animals were accessed daily 
without sedation for obtaining up to 100  µl of blood 
through standardized ear-prick procedures, similar 
to the collection of blood from a human finger-prick. 
This blood was used to perform complete blood counts 
(CBCs) as well as enumerate reticulocytes and parasites 
during the infection.
Animal use
Five healthy, male malaria-naïve M. mulatta (RFa14, 
RIc14, RMe14, RSb14, RFv13) born and raised at the 
Yerkes National Primate Research Center (YNPRC), an 
Association for Assessment and Accreditation of Labo-
ratory Animal Care (AAALAC) international-certified 
institution, were assigned to this study. The animals were 
socially housed in pairs at YNPRC during the experiment, 
and all housing was in compliance with Animal Welfare 
Act regulations as well as the Guide for the Care and Use 
of Laboratory Animals. Males were designated to eliminate 
confounding factors studying anaemia that could be attrib-
uted to loss of blood during the female menstrual cycle. An 
additional rhesus monkey was assigned at the Centers for 
Disease Control and Prevention (CDC) and utilized for the 
generation of sporozoites. Standard procedures for moni-
toring the clinical conditions of the animals, collecting 
biological samples (venous blood and bone marrow aspi-
rates), and performing mosquito feedings on infected ani-
mals to generate infectious salivary gland sporozoites were 
approved by Emory University’s or the CDC’s IACUC and 
followed accordingly. All non-human primates used in this 
study were provided regular environmental enrichment 
opportunities consisting of daily feeding enrichment, pro-
vision of manipulanda, and physical enrichment. Subjects 
were regularly monitored for any behavioural signs of dis-
tress by YNPRC behaviour management personnel. Ani-
mals were trained using positive reinforcement to allow 
blood collections from the ear without sedation.
Parasite selection
Plasmodium cynomolgi B strain was selected for infec-
tions because the relapse pattern of this strain had been 
characterized previously [32], providing confidence that 
relapse infections would be observed within the 100-day 
experimental infection period, based on an inoculum size 
of 2000 freshly dissected salivary gland sporozoites. This 
strain was also selected because of the availability of its 
reference genome [26], needed for retrospective system 
biology studies on the samples that were collected and 
stored for such purposes.
Sporozoite generation and inoculation
To generate sporozoites, a donor rhesus macaque 
was infected with blood-stage parasites that were 
reconstituted from P. cynomolgi B strain, ring-stage 
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Fig. 1 Study design, parasitaemias and treatment regimens of rhesus macaques infected with Plasmodium cynomolgi sporozoites. a Longitudi‑
nal study design to collect whole blood and bone marrow aspirates for current and retrospective analyses at critical infection points as indicated 
(yellow). b Log10 parasitaemia and treatment regimens for the five rhesus macaques infected with 2000 P. cynomolgi B strain sporozoites on day 0 
are shown. Whole blood and bone marrow aspirate sample collections are marked in yellow for each animal and correspond with critical infection 
points depicted in Panel a and summarized in Table 1. Sub‑curative and curative blood‑stage treatments were administered as needed based on 
the clinical complications that occurred during the primary infection and to ensure bona fide relapses. c The mean of the peak parasitaemias for the 
primary and first relapses of RIc14, RSb14, RMe14, and RFa14 are shown. Statistical significance was assessed by a Wilcoxon‑Matched pairs sign rank 
test; p‑values less than 0.05 were considered significant
Table 1 Criteria for the collection of samples at different experimental periods
a The specific criteria and observations at sample collection points during the infection were recorded for each animal based on the clinical assessments made by 
veterinary staff and investigators
Experimental period Criteriaa
Pre‑infection Normal motor activity and appetite
Haematological parameters within normal range
Acute primary Prostration, lethargy, low appetite
Moderate to severe anaemia, thrombocytopaenia, tachypnea, hyperparasitaemia, impaired consciousness, hyperpyrexia, 
azotemia, hyponatremia, hyperkalaemia and clinical evidence of activated coagulation (e.g., petechiae)
Post peak Moderate anaemia, reticulocytemia, control of parasitaemia
Relapse Low parasitaemia
Inter‑relapse Haematological parameters within normal range, no parasitaemia
Final Haematological parameters within normal range
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cryopreserved stocks maintained by the malaria branch 
at the CDC. Prior to the start of this study, the identity 
of these parasites was verified by Illumina 454 sequenc-
ing and comparison to the reported genome sequence of 
Tachibana et  al. [26]. Laboratory-bred Anopheles dirus, 
Anopheles gambiae and Anopheles stephensi mosquitoes 
were fed on the donor monkey using standard, IACUC-
approved procedures after observance of male and 
female gametocytes in the blood. Successful infection 
of the mosquitoes was confirmed within a 7-day period 
post feeding via midgut dissections to monitor oocyst 
development and the progression of the infections with 
sporozoites detected in the salivary glands on days 11 
and 12 after mosquitoes fed on infected blood. The sali-
vary glands were freshly dissected from the infected mos-
quitoes and immediately processed by repeated passage 
through a 26G needle ten times to release sporozoites in 
RPMI-1640 culture media supplemented with 10 % fetal 
calf serum (FCS) on ice. The processed salivary gland and 
other mosquito debris were allowed to settle by gravity 
and the sporozoites in the supernatant were washed once 
by centrifugation at 1000×g in sterile culture medium 
with 10  % FCS. Sporozoite concentrations were deter-
mined by counting in a neubauer hemocytometer cham-
ber using a light microscope at 400× magnification. 
Isolated sporozoites were re-suspended in sterile RPMI 
1640 with 10 % FCS, and the macaque cohort infections 
were initiated by the intravenous inoculation of 2000 
sporozoites per animal.
Clinical monitoring
Blood samples were collected daily from the monkey 
cohort from day −1 to 100 into EDTA-coated capillary 
tubes using standardized, IACUC-approved, ear-prick 
procedures. These samples were used to perform CBCs 
using an automatic cell analyzer (Beckman AcT-diff; 
Coulter Corporation) and reticulocyte enumeration using 
new methylene blue staining of thin blood smears. Clini-
cal data were reviewed with parasitological data daily to 
monitor the clinical conditions of the animals and deter-
mine when specimens should be collected based on the 
criteria noted in Table 1.
Parasite enumeration
Parasitaemia counts (parasites/µl) were determined 
daily via microscopy readings of thick and thin blood 
films stained with a modified Wrights–Giemsa using 
enumeration protocols recommended by the World 
Health Organization (WHO) [39]. Briefly, the number 
of infected RBCs (iRBC) observed on thick blood smears 
per 500 leukocytes was recorded, and the parasitaemia 
determined by multiplying the percentage of parasites 
out of the total number of leukocytes with the leukocyte 
concentration obtained from the CBC. When parasi-
taemia readings were at or greater than 1 %, thin blood 
smear counts were obtained by counting the number of 
infected RBCs out of a total of 1000–2000 RBCs. The 
percentage of infected RBCs was then calculated, and the 
RBC concentration from the CBC was used to determine 
the parasitaemia (parasites/µl). The per cent of iRBCs (or 
per cent parasitaemia) was also calculated by dividing 
the number of parasites by the RBC count and multiply-
ing by 100. To ensure accuracy, two expert microscopists 
independently determined the parasitaemias each day. If 
a significant discrepancy was observed (e.g.   ≥2 stand-
ard deviations of the mean) and/or if unexpectedly low 
or high parasitaemia readings were reported, a third, 
independent senior expert microscopist was designated 
to provide an additional parasitaemia reading. All three 
parasitaemia counts were compared, and the defini-
tive parasitaemia was typically based on the average of 
the two counts that were the closest together. In other 
cases, primarily while verifying the presence of relapses 
with low parasitaemias or after sub-curative blood-stage 
treatment, the third microscopist’s counts were used as 
the decisive readings. For relapse verification, the third 
microscopist counted the number of parasites per 2000 
white blood cells (WBCs), which quadrupled the level of 
sensitivity of the assay.
Specimen collections
Peripheral blood and bone marrow aspirate samples were 
collected prior to infection and during the infections 
(Fig.  1a) for immediate analyses and projected future 
multi-omic studies (e.g., transcriptomics, proteomic, lipi-
domics, metabolomics, and immunological profiling) to 
be performed and integrated with the clinical and para-
sitological data described here. The animals were anes-
thetized with ketamine, and blood and bone marrow 
aspirates were collected from the femoral vein and iliac 
crest, respectively. Venous and capillary blood samples 
were collected in EDTA using either BD vacutainer or 
capillary tubes, respectively, for haematological assays, 
e.g., CBCs and reticulocyte enumeration, and for parasite 
enumeration. Blood for clinical chemistry analyses was 
collected in lithium heparin tubes.
Clinical definitions
Clinical definitions were based on reference values for 
rhesus macaques as defined at the YNPRC and other 
available literature [40]. The normal range of haemoglo-
bin concentration for male rhesus macaques is 12–14 g/
deciliter (dl) and anaemia can be similarly defined in 
humans. Here, anaemia was defined as severe (<7  g/
dl), moderate (7–10  g/dl), or mild (10–11  g/dl), based 
on the haemoglobin nadir, or the lowest level, during 
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the primary infection and relapses. Anaemia was fur-
ther classified as normocytic (63.7–86.9  femtolitres (fl), 
microcytic (<63.7  fl) or macrocytic (>86.9  fl) based on 
the mean corpuscular volume (MCV). Thrombocytopae-
nia was defined as having a platelet count below 150,000 
platelets/µl during either the primary or relapse infec-
tions, and severe thrombocytopaenia was defined as hav-
ing a platelet count of <50,000 platelets/µl.
Therapeutic interventions
WHO criteria for the management of severe malaria were 
utilized as a guide to determine when animals were pro-
gressing towards severe disease and necessitated clinical 
and/or therapeutic intervention to ward off terminally 
severe outcomes [41]. Animals that developed clinical 
complications associated with severe malaria during the 
acute infection periods were administered a sub-curative 
anti-malarial treatment of 1  mg/kg artemether. Addi-
tionally, severe anaemia (<7  g/dl) was treated with IV 
fluid support and whole blood transfusion, also guided 
by YNPRC veterinarian recommendations and IACUC-
approved procedures. After collecting the specimens 
for the post-peak infection point (Fig.  1a), blood-stage 
infections were cured with artemether administered at 
4  mg/kg on the first day of treatment and 2  mg/kg/day 
for 7 days thereafter. This ensured that subsequent blood-
stage parasitaemias detected in the animals were the 
result of relapses from the activation of hypnozoites, and 
not recrudescences of sub-patent, persisting blood-stage 
forms. Curative blood-stage treatment with artemether 
was also administered using this same regimen after each 
relapse, and a curative course of chloroquine (15 mg/kg/
day for 3  days administered intramuscularly) and pri-
maquine (1  mg/kg/day for 7  days administered orally) 
was administered at the end of the entire experiment to 
treat the blood stages and the hypnozoites, respectively.
Statistical analysis
Non-parametric statistical approaches were used to assess 
statistical significance. A Friedman test was performed fol-
lowed by Dunn’s Multiple Comparison post hoc analysis 
to identify significant changes in clinical parameters from 
pre-infection values over time and between pre-, primary, 
and relapse infection values. Spearman’s non-parametric 
correlation analysis was performed on clinical parameters 
using clinical values obtained from the defined experi-
mental periods to ensure that different sample types (i.e., 
venous blood collected at major infection points vs capil-
lary blood collected daily) did not influence associations. A 
Wilcoxon matched-pairs rank sums test was performed to 
compare the primary and relapse infection parasitaemias. 
Both Graphpad Prism Version 6 and JMP Version 12 were 
used for statistical analysis.
Data management and release
All samples were tracked with barcodes and a Labora-
tory Management Information System (LIMS). Data 
that were manually generated, e.g., clinical assessments, 
parasitaemias, animal handing, treatment, diet, snacks, 
and procedures were entered into the LIMS or electronic 
spreadsheets with double-data entry to increase accu-
racy. Data fields were constrained with limits or popu-
lated with pull-down lists of allowable values to further 
increase accuracy. All data were then transferred to 
internal repositories for validation and integration with 
other data. Standard operating procedures (SOPs) for 
all methods were collected and archived. Data derived 
from blood and bone marrow samples were associated 
with the appropriate animal and experimental metadata 
via a barcode. All data associated with this study (clini-
cal, experimental, SOPs, and data dictionary to define 
all terms) were backed-up locally as well as off-site. 
The dataset supporting the conclusions of this article is 
included with the article as Additional file 1 and is also 
being made available via the freely accessible database, 
PlasmoDB [42], as no archival repositories exist for these 
types of data. This experiment is known in the deposited 
files as MaHPIC Experiment 4 (E04).
Results
Primary and relapsing parasitological profiles of P. 
cynomolgi B strain in M. mulatta during a 100‑day 
experimental infection
Intravenous inoculation of approximately 2000 freshly 
isolated salivary gland sporozoites produced patent infec-
tions within 10 to 12  days (mean ±  SE =  11.2 ±  0.37) 
consistent with previous literature (Fig.  1b; [17, 32]). 
The maximum parasitaemias during the primary infec-
tions ranged from 269,962 to 1,214,842 parasites/µl 
(4.42–19.5 % iRBC) between days 18–20 post-inoculation 
(Fig. 1b). RFa14, RMe14 and RFv13 required sub-curative 
treatment with artemether (1  mg/kg) as noted due to 
clinical complications (see Table 2). These interventions 
were implemented to avoid negative outcomes, includ-
ing possible death. RFa14 and RMe14 developed recru-
descent infections 48–72  h later, as anticipated based 
on prior experience with sub-curative artemether treat-
ments of P. cynomolgi and P. coatneyi in rhesus macaques 
at the CDC and the YNPRC [43]. RFv13 subsequently, 
despite the treatment, developed severe clinical compli-
cations, which required this animal to be euthanized, per 
IACUC guidelines and protocols (Fig.  1b). In summary, 
this animal presented with acute renal failure. RSb14 
and RIc14 did not require sub-curative treatment. These 
animals were able to control their primary parasitaemia, 
presumably through an immune mechanism, resulting in 
an approximate ten-fold reduction in parasite levels from 
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about 300,000 parasites/µl down to 4000–8000 parasites/
µl between days 18–23 post-inoculation (Fig.  1b). This 
reduction in parasitaemia was then followed by a rise 
again to nearly peak parasitaemia levels, which is charac-
teristic of most P. cynomolgi infections (Fig. 1b; [17]).
To distinguish relapses from possible recrudes-
cences of persisting low-level blood-stage parasi-
taemias, RIc14, RSb14, RFa14, and RMe14 received 
curative blood-stage treatment with artemether after 
their primary parasitaemia and illness. Artemether 
was administered uniformly on day 26 at 4 mg/kg, and 
then 2  mg/kg/day for 7  days thereafter (Fig.  1b). Dur-
ing the 100-day experiment, RIc14 and RSb14 experi-
enced two relapses, whereas RFa14 and RMe14 had a 
single relapse (Fig.  1b). RIc14 and RSb14 experienced 
their first relapse within 19 and 26  days (day 51 and 
day 58 post-inoculation), respectively, after completion 
of curative blood-stage treatment on day 32 (Fig.  1b). 
Contrastingly, RFa14 and RMe14 remained negative by 
microscopy during this period (Fig. 1b). Curative anti-
malarial treatment for blood stages was administered 
to all animals on day 63, and relapse infections were 
detected as early as 10  days after the completion of 
this second curative blood-stage treatment. All animals 
relapsed prior to the end of the 100-day study, after 
the second round of curative blood-stage treatment; 
RIc14 on day 83 and RSb14 on day 88, with RFa14 and 
RMe14 relapsing for the first times on day 95 and day 
80, respectively.
The peak parasitaemia for the first relapse infections 
ranged from 846 to 11,584 parasites/µl, which was strik-
ingly lower than the primary infection (Fig.  1c). Since 
the animals as a group experienced either one or more 
relapses, this comparison was performed using the maxi-
mum parasitaemia for the first relapse noted for each 
individual. This result was not statistically significant 
(p = 0.0625) however, based on the four of five animals 
remaining in the study. A follow-up study will expand on 
these numbers. Contrary to a previous report stating that 
relapse parasitaemias decrease with subsequent relapses 
[19], a large difference in parasitaemia was not observed 
between the first and second relapses for RSb14 and 
RIc14 (Fig. 1b).
Different degrees of anaemia were observed during the 
primary blood‑stage infections
The primary P. cynomolgi B strain blood-stage infection 
resulted in anaemia in the entire cohort (Fig. 2a, b). Simi-
lar to anaemia in humans with malaria, inter-individual 
differences in anaemia severity were evident and ranged 
from moderate (7–10  g/dl) to severe (<7  g/dl) (Fig.  2b; 
Table 2). The anaemia was normocytic (defined as 63.7–
86.9  fl) based on MCV values (Fig.  2c). Although para-
sitaemia and haemoglobin concentration were negatively 
correlated (Spearman ρ = −0.7288, p < 0.0001), a statis-
tically significant decrease in haemoglobin concentra-
tion compared to pre-infection values did not coincide 
with the peak of parasitaemia during the acute, primary 
phase of the infection (p  >  0.05; Fig.  2a, b). Rather, the 
haemoglobin concentrations were significantly lower 
than pre-infection values approximately 4–7  days after 
the recognized peak of parasitaemia, a period termed 
here as the ‘post-peak of parasitaemia’ (Fig. 2a, b). Dur-
ing this period, the macaques were either controlling the 
infections naturally leading to decreases in parasite num-
bers, or recovering from the infections after the adminis-
tration of a sub-curative dose of artemether. Importantly, 
anaemia to some degree was observed irrespective of the 
administration of sub-curative treatment (Fig. 2b).
Reticulocytes were enumerated to monitor the clinical 
situation, the animals’ attempts to recover from anae-
mia, and as a peripheral indicator of erythropoiesis in 
the bone marrow. Under homeostatic conditions, reticu-
locyte release will coincide with decreases in peripheral 
haemoglobin concentration to compensate for the loss 
of RBCs in the periphery. Thus, reticulocyte concentra-
tions should increase during the acute, primary infection 
period and begin to return to pre-infection levels after 
the peak of parasitaemia. Contrary to this hypothesis, 
the reticulocyte concentrations did not increase from 
Table 2 Clinical summary and phenotype classification of rhesus macaques infected with Plasmodium cynomolgi B strain
RSb14 RIc14 RFa14 RMe14 RFv13
Anaemia (Degree) Yes (Moderate) Yes (Moderate) Yes (Moderate) Yes (Severe) Yes (Severe)
Thrombocytopaenia Yes Yes Yes Yes Yes
Unique sign None None Petechiae None None
Sub‑curative treatment No No Yes Yes Yes
Additional clinical interventions None None None Blood transfusion Blood transfusion
Clinical phenotype classification Non‑severe Non‑severe Severe Severe Lethal
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pre-infection levels until the post-peak parasitaemic 
phase when the animals were beginning to show signs 
of recovery (Figs.  3a, b, c). Curiously, there was a small 
increase in reticulocyte concentrations between approxi-
mately days 8 and 15 post-inoculation for all animals 
except RFv13 (the animal with the most severe disease), 
followed by an immediate decrease back to pre-infection 
levels whenever parasitaemia began to increase exponen-
tially (Fig. 3b, c).
Thrombocytopaenia developed during the primary 
blood‑stage infections
Thrombocytopaenia, a clinical condition that is the result 
of reduced number of platelets in the blood, is a com-
mon haematological finding during malaria, but its spe-
cific role in pathogenesis has been highly debated [14, 
44–48]. Indeed, thrombocytopaenia (<150,000 platelets/
µl) was observed in all macaques (Fig. 4a, b). Despite the 
decrease below a clinically relevant threshold, the drop 
Fig. 2 Plasmodium cynomolgi B strain infection in rhesus macaques induces moderate to severe anaemia. a Haemoglobin concentrations of five 
rhesus macaques are shown prior to infection, during the acute primary, and after the peak of parasitaemia. b Haemoglobin kinetics in relation to 
parasitaemia and the relationship between haemoglobin and MCV (c) for up to 100 days after inoculation are shown. Orange bars in Panel B indicate 
when peripheral blood and bone marrow aspirates were collected for retrospective systems biology analysis. Statistical analysis was performed by a 
Friedman’s Test with Dunn’s multiple comparison post‑hoc for Panel a; *p < 0.05, ns not significant
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in platelet concentration was not statistically significant 
from pre-infection values (p  >  0.05), and furthermore, 
severe thrombocytopaenia (<50,000 platelets/µl) was not 
observed (Fig. 4a, b). Thrombocytopaenia was most pro-
nounced at day 20, near the peak of parasitaemia, where 
the peripheral platelet concentrations were approxi-
mately 38 % of the baseline levels (Fig. 4b, c). The recov-
ery of platelets coincided with a decrease in parasitaemia 
between days 20 and 26, irrespective of the administra-
tion of sub-curative blood-stage treatment or self-control 
of the infections (Fig. 4b). Notably, platelet concentration 
in the periphery increased to higher than pre-infection 
values before stabilizing (Fig. 4b, c).
Thrombocytopaenia is thought to be the result of a 
variety of mechanisms, including the binding of plate-
lets to infected RBCs, removal of platelets by phagocytic 
Fig. 3 Insufficient erythropoietic output is a feature of Plasmodium cynomolgi B strain infection. a Reticulocyte Concentration of five rhesus 
macaques are shown prior to infection, during the acute primary, and after the peak of parasitemia. b Reticulocyte dynamics in relation to para‑
sitemia for up to 100 days after inoculation are depicted. Orange bars indicate when peripheral blood and bone marrow aspirates were collected 
for retrospective systems biology analysis. c The relationship between hemoglobin and reticulocyte concentrations are shown for up to 100 days 
after inoculation. Statistical analysis was performed by a Friedman’s Test with Dunn’s multiple comparison post‑hoc for Panel a; *p < 0.05, ns not 
significant
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cells and sequestration of the platelets in the micro-
vasculature and organs [14, 16, 37]. Here, a decrease 
in mean platelet volume (MPV) was noted whenever 
platelet concentrations were beginning to return to pre-
infection levels, between days 20 and 30 post-inoculation 
(Fig.  4d). Alterations in MPV could indicate that plate-
let production by megakaryocytes in the bone marrow 
was disrupted, providing another mechanism that could 
potentially contribute to thrombocytopaenia. In addition 
to impaired production of platelets, a lower MPV could 
be caused by low platelet concentrations. However, the 
current data do not support this explanation, because 
as platelet concentrations returned to pre-infection lev-
els the MPV decreased (Fig.  4d). Furthermore, MPV 
and platelet concentration were inversely correlated 
(Spearman ρ = −0.3785, p < 0.0358) (Fig. 4d). To further 
Fig. 4 Plasmodium cynomolgi B strain infection results in thrombocytopenia during the acute primary infection. a The mean platelet concentrations 
before infection, during the acute primary, and post peak of parasitemia are shown. b Parasitemia in relation to platelet concentration is shown for 
each macaque. Orange bars indicate when peripheral blood and bone marrow aspirates were collected for retrospective systems biology analysis. c 
Parasitemia in relation to the percent of pre‑infection platelet values is shown. d The mean platelet volume in relation to the platelet concentration 
is shown. Statistical analysis was performed by a Friedman’s Test with Dunn’s multiple comparison post‑hoc for panel a and no statistical significance 
was found
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evaluate the hypothesis that megakaryocyte function 
could be compromised during cynomolgi malaria, the 
dynamics of reticulocyte release and platelet recovery 
were examined. If platelet and/or reticulocyte production 
were compromised due to altered bone marrow physiol-
ogy, then the recovery of these cell types in the periphery 
may overlap. Indeed, the increase of platelet concentra-
tions after the primary blood-stage infections coincided 
with increases in peripheral reticulocyte concentrations 
(Fig. 5).
Relapses did not result in significant changes in clinical 
parameters
One of the primary goals of this study was to better 
understand the clinical aspects of relapses compared to 
primary blood-stage infections. Analyses focused on the 
first relapses, with comparisons across the four animals 
that survived the primary infection. Importantly, sig-
nificant changes were not observed in parasite burden 
(Fig.  1b), haemoglobin (Fig.  2b), reticulocyte (Fig.  3b), 
or platelet concentrations (Fig.  4b) during the second 
relapses compared to the first. Relapses did not result in 
the same changes in clinical parameters as the primary 
infections and did not differ significantly from pre-infec-
tion values (Fig. 6a, b, c).
RMe14, the macaque with the highest parasitaemia dur-
ing a relapse, was the only animal that developed minor 
alterations in haemoglobin, platelet and reticulocyte con-
centrations during relapses (Figs.  2b, 3b, 4b). Specifically, 
the haemoglobin level for this animal dropped from 14 g/dl, 
recorded 7 days before the peak of the relapse parasitaemia, 
to 11 g/dl, making it mildly anaemic (Fig. 2b). Unlike during 
the period of the primary blood-stage infection, the drop in 
haemoglobin concentration resulted in an increase in the 
peripheral reticulocyte concentration, suggesting that the 
mechanism(s) that prevented the compensatory release of 
reticulocytes to compensate for alterations in haemoglobin 
concentration during the primary infection did not occur 
during relapse infections, likely due to the controlled para-
site burden (Fig.  3b). Platelet concentration also dropped 
sporadically during relapses for this animal (Fig. 4b).
Clinical presentations ranged from non‑severe to lethal
A variety of clinical phenotypes were observed in this 
study, which could be distinguished as non-severe, 
severe and lethal (Table  2). RIc14 and RSb14 were able 
to control the primary infection without sub-curative 
blood-stage treatment and displayed mild thrombocyto-
paenia and moderate levels of anaemia. Thus, these two 
animals were classified as non-severe. Contrastingly, 
RFa14, RMe14 and RFv13 required sub-curative treat-
ment during the primary blood-stage infection due to a 
variety of adverse clinical signs. RFa14 presented with a 
unique phenotype characterized by a drop in haemoglo-
bin to approximately 11.2 g/dl and platelet concentration 
to approximately 125,000 platelets/µl in the peripheral 
blood early during the primary infection, and uniquely, 
petechiae were noticed on the trunk of this animal.
This profile was consistent with that reported with a P. 
coatneyi infection in a rhesus macaque, where the animal 
progressed to very severe disease due to disseminated 
intravascular coagulopathy [49]. Due to the poor prog-
nosis associated with these indications, RFa14 was sub-
curatively treated and classified as severe. Contrastingly, 
RMe14 and RFv13 developed severe anaemia (<7  g/dl) 
during the primary infection (Fig. 2b). In response to this 
presentation, sub-curative blood-stage treatment was 
administered and whole blood transfusions performed 
for both of these animals. RMe14 recovered and was cat-
egorized as having a severe clinical phenotype, but RFv13 
succumbed to the infection as noted above despite this 
intervention, resulting in the additional classification as a 
lethal clinical phenotype.
Parasitaemia and the lack of an increase in reticulocytes 
during the initial phase of the primary infection 
distinguish the lethal clinical phenotype
The contribution of parasite burden to each clini-
cal phenotype was evaluated. The peak parasitaemia 
in the non-severe animals was 273,509 and 305,636 
(mean  =  289,573) parasites/µl whereas the two severe 
animals that survived had parasitaemias of 309,365 and 
379,140 (mean  =  344,452) parasites/µl during the pri-
mary infection (Figs.  1b, 7a). Using this measure, the 
Fig. 5 Reticulocyte and platelet concentrations recover at a similar 
rate after the acute primary infection. The reticulocyte and platelet 
concentration are shown for up to 100 days after infection of rhesus 
macaques with P. cynomolgi B strain
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parasitaemia was not strikingly different between the 
non-severe and severe clinical phenotypes. Next, the 
peripheral parasitaemias were analysed as a percentage, 
or the number of infected RBCs out of the total RBCs. 
Using this approach, there was possibly a minor differ-
ence between the two phenotypes. Specifically, the non-
severe animals had parasitaemias of 4 and 5  % whereas 
the severe animals had parasitaemias of 6.3 and 7.8  %, 
prior to administration of the sub-curative blood-stage 
treatments (Fig.  7b). The animal that succumbed to the 
infection developed a maximum parasitaemia of approx-
imately 1,200,000  parasites/µl and showed a 19.5  % 
parasitaemia prior to clinical intervention, which was 
approximately four-fold higher than observed in the sur-
viving animals (Fig. 7a, b).
Unexpectedly, one other clinical feature in addition 
to parasite burden was identified that distinguished the 
lethal from the non-severe and severe phenotypes. Even 
though the haemoglobin concentrations and platelet 
kinetics for the non-severe, severe and lethal phenotypes 
were all similar during the primary blood-stage infec-
tions (Fig.  7c, d), the reticulocyte kinetics for the lethal 
infection (RFv13) were not the same as for the other two 
phenotypes (Fig.  7e). Specifically, as noted above, the 
peripheral reticulocyte concentrations in this animal did 
not show a modest increase during the patent blood-
stage infection between days 10–15 post-inoculation, in 
comparison to the other animals where a modest, short-
term increase was evident (Fig.  7e). This difference in 
reticulocyte kinetics could indicate that this and possibly 
other early host responses may influence and be a predic-
tor of clinical complications and the potential course of 
the disease state or recovery processes.
Discussion
This 100-day experiment was designed to study the clini-
cal and parasitological attributes of the primary blood-
stage and relapse infections caused by P. cynomolgi in 
rhesus macaques and set the stage for future, comprehen-
sive studies using this model to understand the underlying 
Fig. 6 Homologous relapses induce minimal, if any, changes in clinical parameters from pre‑infection values. The average of haemoglobin concen‑
trations (a), platelet nadirs (b), and maximum number of reticulocytes (c) for RMe14, RFa14, RIc14, and RSb14 prior to infection, during the primary 
infection, and for relapses are shown. Statistical significance was assessed by a Friedman’s Test with Dunn’s multiple comparison post hoc analysis. 
pvalues less than 0.05 were considered significant; *p < 0.05; ns not significant
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mechanisms of immunity, pathogenesis and disease. 
Highly resolved kinetics of core haematological param-
eters were developed after inoculation with infectious B 
strain sporozoites, and specifically, reticulocyte, platelet, 
haemoglobin, MPV, and MCV dynamics are presented 
here. This study expands upon previous rhesus infection 
studies with the P. cynomolgi B strain, which primarily 
monitored parasitological data but did not assess clinical 
parameters on a daily basis [17, 32]. The compiled clini-
cal and parasitological datasets generated here provide a 
glimpse into the daily dynamics of malaria beyond what 
is typically feasible in humans. It is anticipated that data 
generated in this experiment (all of which are being 
shared publicly—see “Methods” section and Additional 
file 1) will aid the development and testing of hypotheses 
by the research community whether for clinical studies or 
continued investigations using P. cynomolgi as a model.
Anaemia ranged from mild to severe during the pri-
mary infections in this study and appears to be the result 
of multiple processes. First, it is noteworthy that haemo-
globin decreased to the lowest levels after parasitaemia 
was reduced, whether from the natural control of the 
infection by the macaque or drug treatment. This data 
demonstrates that the loss of RBCs due to parasitism is 
not the sole reason for anaemia in this model. Indeed, 
other non-human primate malaria models [43], rodent 
malaria models [13] and humans [50, 51] show a similar 
kinetic where anaemia is worse after the peripheral para-
sitaemia has decreased. This phenomenon is attributed to 
the simultaneous removal of iRBCs and uninfected RBCs 
[52, 53], which has also been modelled mathematically to 
arrive at similar conclusions [50]. Secondly, the normal, 
timely replenishment of circulating RBCs by the release 
of reticulocytes from the bone marrow was disrupted, 
Fig. 7 Higher parasitaemia and less reticulocytes during early infection distinguish the lethal cynomolgi malaria infection. Parasitaemia (a, b), 
haemoglobin (c), reticulocyte (d), and platelet (e) kinetics are shown comparing the three different cynomolgi infection clinical phenotypes. The 
average of the two non‑severe and two severe animals were used for each point on the graph; since the lethal phenotype is unique, a single 
animal’s values were used
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as shown previously with P. coatneyi infection of rhesus 
macaques [43]. Thus, the disruption of compensatory 
bone marrow mechanisms with the effective release and/
or production of reticulocytes from the bone marrow is 
likewise apparent in the P. cynomolgi-rhesus macaque 
model during the acute, primary infection. For each of 
these species, which model P. falciparum and P. vivax, 
respectively, the disruption of normal bone marrow 
physiology could be potentially due to ongoing immuno-
logical responses against the parasite or parasite byprod-
ucts, such as haemozoin, that are released as the parasites 
multiply in the blood [13, 54–56]. In agreement as shown 
here, there was an initial increase of reticulocytes early 
during the primary infections and these cells returned 
to baseline levels when the parasitaemia was increasing 
exponentially in the blood. This supports the view that 
the disruption of the normal compensatory mechanisms 
is dependent on parasite levels. Future studies will be 
needed to better understand the host-pathogen interac-
tions that occur during the primary infection and how 
they contribute to malarial anaemia in this model.
The relative contribution of thrombocytopaenia to dis-
ease outcome during malaria remains controversial and 
also not well understood [14, 44, 47]. In this study, all 
animals developed mild thrombocytopaenia irrespective 
of their clinical presentations, and thus, thrombocyto-
paenia was not viewed as an indicator of disease severity 
or outcome. Prior evidence suggests that thrombocy-
topaenia could be due to removal of platelets by splenic 
macrophages during infection [16], whereas other mod-
els suggest that platelets form clumps with iRBCs [57] or 
become sequestered in the microvasculature by adher-
ing to activated endothelial cells [58]. Interestingly, pub-
lished experiments with the P. cynomolgi B strain have 
demonstrated that thrombocytopaenia occurs in both 
spleen-intact and splenectomized macaques, suggesting 
that there are other contributing factors in the develop-
ment of this complication aside from processes associ-
ated with this organ [59]. In agreement, the data from 
this study indicates that platelet production may have 
been impaired since the MPV was decreased as the num-
ber of platelets rebounded after the peak of parasitaemia. 
Previous studies with malaria patients have reported 
changes in MPV during malaria [16, 60]. The alteration 
in MPV may indicate disruption of megakaryocyte func-
tion, and thus, platelet production. In further support of 
this hypothesis, both reticulocytes and platelets returned 
to pre-infection levels together, and since both of these 
cell types originate from the bone marrow, the simulta-
neous return to normal levels could be explained by the 
restoration of normal bone marrow physiology. Overall, 
these data suggest that the disruption of normal bone 
marrow physiology during acute malaria may also lead to 
impaired platelet production and contribute to thrombo-
cytopaenia. Future studies should explore this hypothesis 
further and aim to understand if thrombocytopaenia is, 
in part, a bystander effect of bone marrow dysfunction.
It is important to recognize that macaques infected 
with P. cynomolgi presented with inter-individual differ-
ences in disease severity, similar to humans. In RFv13, a 
very high parasitaemia (19.5  % parasitaemia), appeared 
to contribute to the lethality since this parasitaemia 
clearly distinguished this animal from the two non-severe 
(RSb14 and RIc14) and two severe (RMe14 and RFa14) 
clinical presentations. These phenotypes did not clearly 
stratify away from each other based on parasitological 
profiles alone, indicating that while parasitaemia may 
play a role in severe disease, it is not solely responsible 
for the observed differences in clinical presentation and 
other pathological processes may come into play. This 
is reminiscent of human malaria where individuals can 
progress to severe malaria regardless of parasitaemia 
[61–63]. Curiously, unlike the four surviving macaques, 
RFv13 did not show a modest increase in reticulocytes 
during the beginning of the primary infection. In future 
studies, it would be useful to evaluate this finding and 
other potential indicators of the progression of infections 
and how these early responses to blood-stage infections 
influence pathogenesis and clinical presentation.
Schmidt [32] demonstrated that relapse frequencies in 
the rhesus macaque differ based on the number of P. cyn-
omolgi B strain sporozoites inoculated, and based on this 
evidence, some investigators have used 1 × 106 sporozo-
ites to generate early, frequent and uniform relapse pat-
terns across individuals for screening anti-hypnozoite 
drugs [19]. In contrast, only about 2000 sporozoites were 
inoculated in the current study, aiming for primary infec-
tions followed by more natural patterns of relapse. While 
this is still higher than what is suspected to be naturally 
injected by a mosquito [64, 65], 2000 sporozoites best 
ensured at least one or two relapses in all animals during 
the course of this study. In fact, the average number of 
relapses observed was 1.5. This number may have been 
higher if the animals had not been cured as a group after 
the fifth specimen collection. Nevertheless, the observed 
relapse patterns reported here are similar to what would 
be expected with P. vivax infections with tropical strains 
of this parasite [7, 66, 67]. A follow-up, iterative experi-
ment was designed to monitor the natural relapse pat-
terns, without such treatment plans, and to monitor 
gametocytes during the relapse periods more carefully.
Understanding, preventing and treating relapses 
caused by P. vivax, and also P. ovale, remain key chal-
lenges in today’s malaria eradication efforts, especially if 
asymptomatic carriers remain infectious to mosquitoes. 
Critically, the relative impact of primary versus relapse 
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clinical malaria presentations has remained undefined 
in a controlled, experimental model system and direct 
evidence from human studies is not available because 
of the challenges distinguishing the two in human cases 
without a well-controlled study design [68–71]. Here, 
each bona fide relapse, subsequent to blood-stage treat-
ment and in the absence of re-infections, resulted in sig-
nificantly lower parasitaemias compared to the primary 
infections and minimal, if any, changes in clinical param-
eters to indicate illness. This suggests that immunity, or 
potentially other undefined mechanisms, during the pri-
mary infection, led to controlled relapses characterized 
by reduced parasitaemias and lack of clinical complica-
tions. Whenever minor alterations in clinical parame-
ters were observed during a relapse (e.g., minor drop in 
haemoglobin levels from 14 to 11 g/dl), as was the case 
for RMe14, these alterations resolved in a controlled, 
non-pathological manner, without the need for clinical 
support. The lack of clinical illness during relapses was 
not necessarily expected, especially in animals that only 
experienced a single primary blood-stage infection, since 
previous reports have concluded, through mathemati-
cal and statistical modelling of data collected from holo-
endemic areas that relapses are responsible for up to 
96 % of blood-stage P. vivax infections [11, 72]. Thus, this 
experiment draws light to the question “What percent-
age of relapses actually cause clinical malaria?” Relapses 
have been a major concern due to their role in causing 
possible repeated bouts of illness and because they can 
be a source of infectious gametocytes to maintain trans-
mission. The data presented here support the hypothesis 
that relapses may not necessarily be the main cause of 
clinical vivax or ovale malaria cases. This warrants fur-
ther study to understand the clinical outcome of primary 
infections compared to relapses, in addition to transmis-
sibility questions, caused by homologous or heterologous 
strains as would also be anticipated in malaria-endemic 
regions [71, 73, 74].
In a previous study, rhesus macaques infected with 
P. cynomolgi were treated soon after infected RBCs 
were detected, and the parasitaemia of the first relapses 
appeared to be higher than subsequent relapses [19]. 
The clinical status of the macaques during relapses was 
not presented, however, so it is unknown if the clinical 
profile of the relapses differed from the primary infec-
tions. In contrast, the parasitaemia in the current study 
was allowed to persist during the primary infections, 
since a goal was to understand the course of the clinical 
presentations. Interestingly, with this approach, the first 
and second relapses had similar parasitological and clini-
cal attributes, and the difference in parasitaemia between 
the primary infection and relapses was substantial. These 
data highlight the point that the timing of the experimen-
tal treatment of blood-stage infections may affect the 
later presentation of relapses, and could in turn influence 
whether the relapse parasitaemia and illness are sup-
pressed, or not. Future studies should evaluate if the tim-
ing of blood-stage treatment affects the development of 
immunity against the parasite.
As shown by this research team and others using this 
model system, relapse infections can be definitively pro-
duced under controlled experimental conditions [19, 
32], in the absence of new sporozoite-initiated infec-
tions, and they can be distinguished from blood-stage 
recrudescences through the administration of curative 
blood-stage treatments. This creates a clear ‘window’ of 
time after the administration of curative treatment of 
blood-stage infections, during which time the activation 
of hypnozoites and appearance of relapse parasites can 
be anticipated and studied. While a challenging prospect, 
it is during this period that the identification of blood-
based, metabolic biomarkers of liver-stage forms may 
1 day become a reality, paving the way towards diagnostic 
tools and curative liver-stage treatments [75].
Conclusions
The P. cynomolgi-rhesus macaque model is invaluable for 
malaria research, particularly with regard to the direct 
study of both primary and relapse infections and patho-
physiological mechanisms. This study uniquely pro-
vides a day-to-day clinical perspective in haematological 
changes during longitudinal infections, and sets the stage 
for systems biology investigations based on data from a 
few individuals [76, 77]. Here, all five subjects showed 
different degrees of clinical severity. It is anticipated 
that future analyses (immunological, biochemical, etc.) 
using the blood and bone marrow specimens collected 
from this experiment, with the integration of such data 
with the fundamental information presented here, will 
lead to the identification of possible mechanisms and an 
improved understanding of anaemia, thrombocytopae-
nia and relapses. Notably, the current data have provided 
insight into relapse biology by demonstrating that bona 
fide relapses did not result in signs of clinical malaria. 
This was not necessarily expected and is important to 
consider when assessing both the clinical and epidemio-
logical impact of relapses caused by P. vivax and P. ovale.
Additional file
Additional file 1. Haematological and parasitological data of Plasmo-
dium cynomolgi B strain infections in rhesus macaques for up to 100 days. 
The data used in this study are contained within this file with appropriate 
metadata.
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